ERBB2 and breast carcinoma: The modelprovides an anticipated treatment response for both cases with HER2-targetedtherapy and those without.151 A clinicalstudy evaluating the use of [64Cu]-DOTA-trastuzumab inPET for women with advanced HER2-positive breast cancer is at itsfinal stage.